A Phase II multicenter open-label single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase Chronic Myelogenous Leukemia (ASC2ESCALATE)
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
